Abstract
Irinotecan has been increasingly used for treatment of pediatric cancers over the past decade. Irinotecan has modest single-agent activity against common childhood solid tumors, and the low incidence of myelosuppression seen with protracted administration makes it well-suited for combination chemotherapy regimens. Data from mouse xenograft models and clinical trials suggest the activity of irinotecan can be improved by the addition of temozolomide, vincristine, or bevacizumab. These observations have led to focused investigation in at least seven different types of childhood cancer. This report summarizes the progress made in understanding the spectrum of activity, pharmacokinetics, pharmacogenetics, toxicity profile, and mechanisms of resistance of this agent. Also reviewed are the different schedules and routes of administration that have been investigated in pediatric clinical trials. Finally, potential applications for future use are discussed, including novel combinations with targeted therapies.
Keywords: Irinotecan, pediatric cancer, neuroblastoma, Ewing sarcoma, rhabdomyosarcoma.
Current Cancer Therapy Reviews
Title:Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Volume: 6 Issue: 4
Author(s): Lars Wagner
Affiliation:
Keywords: Irinotecan, pediatric cancer, neuroblastoma, Ewing sarcoma, rhabdomyosarcoma.
Abstract: Irinotecan has been increasingly used for treatment of pediatric cancers over the past decade. Irinotecan has modest single-agent activity against common childhood solid tumors, and the low incidence of myelosuppression seen with protracted administration makes it well-suited for combination chemotherapy regimens. Data from mouse xenograft models and clinical trials suggest the activity of irinotecan can be improved by the addition of temozolomide, vincristine, or bevacizumab. These observations have led to focused investigation in at least seven different types of childhood cancer. This report summarizes the progress made in understanding the spectrum of activity, pharmacokinetics, pharmacogenetics, toxicity profile, and mechanisms of resistance of this agent. Also reviewed are the different schedules and routes of administration that have been investigated in pediatric clinical trials. Finally, potential applications for future use are discussed, including novel combinations with targeted therapies.
Export Options
About this article
Cite this article as:
Wagner Lars, Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner, Current Cancer Therapy Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339410793358110
DOI https://dx.doi.org/10.2174/157339410793358110 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diet and Metabolic Syndrome: An Overview
Current Vascular Pharmacology Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy Selecting the Components for a Safe and Efficient Tuberculosis Subunit Vaccine - Recent Progress and Post-Genomic Insights
Current Pharmaceutical Biotechnology The Clinical Relevance of Differential Cell Counts in Induced Sputum and its Relationship with Various forms of Asthma
Current Respiratory Medicine Reviews Towards a Personalised Approach to Managing Influenza Infections in Infants and Children – Food for Thought and a Note on Oseltamivir
Infectious Disorders - Drug Targets The Human Microbiome Project, Personalized Medicine and the Birth of Pharmacomicrobiomics
Current Pharmacogenomics and Personalized Medicine A Refined Framework for Precision and Translational Proteomics in Clinical Research
Current Proteomics Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology Vitamin D Metabolism Genes in Asthma and Atopy
Mini-Reviews in Medicinal Chemistry The Price of the Successful Treatment of Pediatric Malignancies
Current Pediatric Reviews Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Recent Advances in Iron-Catalyzed C-H Bond Activation Reactions
Current Inorganic Chemistry (Discontinued) Advanced Diabetes Care: Three Levels of Prediction, Prevention & Personalized Treatment
Current Diabetes Reviews The Involvement of Uric Acid in the Pathogenesis of Preeclampsia
Current Hypertension Reviews Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology Appropriate Use of Antibiotics for the Management of Respiratory Tract Infections
Infectious Disorders - Drug Targets Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets